-
Promising Early Results: LYMPHIR™ Shows Potential to Enhance CAR-T Therapy in High-Risk DLBCL
NASDAQ: $CTOR Citius Oncology, Inc., a key player in oncology biopharmaceuticals and a subsidiary of Citius Pharmaceuticals, Inc., recently shared encouraging topline safety and efficacy results from an investigator-initiated Phase 1 trial. This study explored the utility of LYMPHIR™ (E7777, denileukin diftitox?cxdl) when administered as a preparatory treatment before commercial CD19-directed CAR-T cell therapy for…
-
Hoth Therapeutics Leverages OpenAI API to Accelerate Development of Orphan Oncology Program, HT-KIT
NASDAQ: $HOTH Hoth Therapeutics, Inc., a biopharmaceutical company dedicated to patient-focused therapies, recently announced a significant strategic move: the deployment of the OpenAI API to bolster the development of its orphan-designated therapy, HT-KIT. This innovative integration targets rare and aggressive KIT-driven cancers, marking a forward-thinking approach to drug development within the oncology space. AI Integration…
-
FREE BIO-TECH STOCK CATALYST REPORT FOR WEEK OF 03-01-2026 TO 03-07-2026
We’re excited to announce the release of our latest free bio tech stock catalyst report for the upcoming week. This new free stock report highlights bio tech companies that have an upcoming important event to help traders and investors make informed decisions in today’s dynamic environment. Each stock symbol is a link to a stock…
-
FREE BIO-TECH STOCK CATALYST REPORT FOR WEEK OF 02-22-2026 TO 02-28-2026
We’re excited to announce the release of our latest free bio tech stock catalyst report for the upcoming week. This new free stock report highlights bio tech companies that have an upcoming important event to help traders and investors make informed decisions in today’s dynamic environment. Each stock symbol is a link to a stock…
$ALDX, $ALXO, $BBIO, $CGEN, $FULC, $GANX, $IMRX, $TARA, $XNCR, ASCO Genitourinary Cancers Symposium, biopharmaceutical, clinical-research, fda, new drug application, Oppenheimer 36th Annual Healthcare Life Sciences Conference, pr-newswire, press-releases, Wells Fargo Executive Biotech Summit, World ADC London 2026 -
FDA Approves Groundbreaking All-Oral, Fixed-Duration Treatment for Previously Untreated CLL
NYSE: $ABBV A Significant Advance in Chronic Lymphocytic Leukemia Treatment The U.S. Food and Drug Administration (FDA) has granted approval for the combination treatment of VENCLEXTA® (venetoclax) and acalabrutinib for adult patients newly diagnosed with chronic lymphocytic leukemia (CLL). This pivotal decision, supported by robust data from the Phase 3 AMPLIFY trial, introduces the first…
-
10x Genomics Scheduled to Present at 46th Annual TD Cowen Health Care Conference
NASDAQ: $TXG 10x Genomics, Inc., a prominent innovator in the fields of single cell and spatial biology, has confirmed its participation in a significant industry event next month. The company announced that key members of its management team are slated to present at the highly anticipated 46th Annual TD Cowen Health Care Conference. The scheduled…
-
Compugen Set to Present at Key Investor Conferences in Early 2026
NASDAQ: $CGEN Compugen Ltd., a clinical-stage company pioneering cancer immunotherapy through advanced AI/ML-powered computational drug target discovery, has announced its management team will be participating in two significant investor conferences in the coming months. These appearances offer an important opportunity for stakeholders to gain insight into the company’s progress across its differentiated pipeline. The first…
-
QuidelOrtho Announces Presentation at Prestigious Raymond James 47th Annual Institutional Investor Conference
NASDAQ: $QDEL QuidelOrtho Corporation, a recognized global leader in innovative in vitro diagnostics, has officially announced its participation in a significant industry event: the Raymond James 47th Annual Institutional Investor Conference. This presentation offers a valuable opportunity for investors, analysts, and industry stakeholders to gain direct insight into the company’s strategic direction, recent performance, and…
-
NeuroSense’s PrimeC Shows Remarkable 65% Reduction in ALS Mortality Risk and Over 14-Month Survival Extension
NASDAQ: $NRSN NeuroSense Therapeutics Ltd., a biotechnology company concentrating on developing treatments for neurodegenerative conditions, has recently released compelling long-term survival data from its completed PARADIGM Phase 2b clinical trial assessing PrimeC for amyotrophic lateral sclerosis (ALS). This extended analysis confirms a clinically significant and statistically robust improvement in overall survival for patients treated with…
-
FDA Greenlights FILKRI™: Accord BioPharma Completes Comprehensive G-CSF Portfolio for Oncology Support
Accord BioPharma Secures FDA Approval for FILKRI™ (filgrastim-laha), Biosimilar to NEUPOGEN® Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd., has announced a significant milestone: the U.S. Food and Drug Administration (FDA) has approved FILKRI™ (filgrastim-laha). This product is a biosimilar to the established reference product, NEUPOGEN® (filgrastim). The approval, announced on February 17,…
-
Bio-Techne’s Ella Platform Secures CE-IVD Mark, Revolutionizing European Immunoassay Testing
NASDAQ: $TECH Bio-Techne Corporation, a leading global supplier of life science tools, reagents, and diagnostic products, has announced a major milestone: the Ella benchtop immunoassay platform has officially achieved CE-IVD marking and is now available for purchase throughout the European Union. This crucial certification opens the door for European clinical laboratories to adopt Ella’s industry-leading…
-
SOPHiA GENETICS Expands U.S. Footprint with Agreements with Two Major Integrated Health Systems
NASDAQ: $SOPH SOPHiA GENETICS, a recognized leader in AI-driven precision medicine, has significantly augmented its presence in the United States through agreements with two substantial, integrated healthcare systems. This expansion marks a pivotal moment in bringing advanced genomic analysis to a wider patient population across key regions. These two newly integrated institutions represent some of…
-
Azenta Life Sciences and Frontier Space Forge Alliance to Advance Research Infrastructure Beyond Earth
NASDAQ: $AZTA A New Frontier for Life Sciences: Azenta Partners with Frontier Space for Space-Based Research Azenta, Inc., a global leader in life sciences solutions, has announced a significant strategic partnership with Frontier Space, a pioneer in commercial space-based research systems. This collaboration marks a pivotal moment, uniting Azenta’s expertise in sample management with Frontier…
-
Eli Lilly Acquires Orna Therapeutics to Pioneer In Vivo Cell Engineering and Advance Next-Generation Therapies
NYSE: $LLY Eli Lilly and Company has announced a significant strategic move to bolster its capabilities in advanced therapeutics by entering into a definitive agreement to acquire Orna Therapeutics, Inc. This acquisition focuses on integrating Orna’s innovative platform for engineering immune cells directly within the body, aiming to revolutionize the treatment landscape for various diseases,…
-
FREE BIO-TECH STOCK CATALYST REPORT FOR WEEK OF 02-08-2026 TO 02-14-2026
Well well, The Seattle Seahawks take the Win in Super Bowl LX. This is what Google’s Gemini summarized regarding stock market prediction after the Win. And now, back to the BIO-TECH STOCK CATALYST REPORT. We’re excited to announce the release of our latest free bio tech stock catalyst report for the upcoming week. This new…
-
Illumina Announces Fourth Quarter and Fiscal Year 2025 Financial Performance
NASDAQ: $ILMN Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025 Illumina, Inc. today announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. The company reported solid performance across its core sequencing segments, reflecting continued momentum in both clinical adoption and research applications globally. Fourth Quarter Financial…
-
Atossa Therapeutics Reinforces Z-Endoxifen’s Value Following Priority Review Voucher Program Reauthorization
NASDAQ: $ATOS Atossa Therapeutics, Inc. has underscored the continued strategic significance of its lead drug candidate, Z-Endoxifen, for the treatment of Duchenne Muscular Dystrophy (DMD). This reinforcement comes directly on the heels of recent legislative action by the U.S. Congress to reauthorize the Priority Review Voucher (PRV) program. Z-Endoxifen and the Importance of the PRV…
-
TransCode Therapeutics and Quantum Leap Advance TTX-MC138 Development with IND Amendment Submission for Phase 2a Trial
NASDAQ: $RNAZ A Significant Step Forward in Oncology Treatment TransCode Therapeutics, Inc. and Quantum Leap Healthcare Collaborative (QLHC) have jointly announced a noteworthy progression in their ongoing research and development efforts. The companies have officially submitted an Investigational New Drug (IND) amendment to the U.S. Food and Drug Administration (FDA). This submission pertains to the…
-
PTC Therapeutics Announces Date for Fourth Quarter and Full-Year 2025 Financial Results
NASDAQ: $PTCT PTC Therapeutics, a biotechnology company focused on developing innovative treatments for rare diseases, has officially announced the date for the release of its financial performance data for the fourth quarter and the entirety of the 2025 fiscal year. Investors, analysts, and stakeholders can anticipate the official announcement on Thursday, February 19, 2026. This…
-
Insmed to Present Fourth Quarter and Full Year 2025 Financial Results
NASDAQ: $INSM Insmed Incorporated has officially announced the schedule for its upcoming financial results presentation. The company will host a conference call to discuss its financial performance for the fourth quarter and the entirety of the fiscal year 2025. This event is set to take place on Thursday, February 19, 2026. The conference call is…
-
Viking Therapeutics Announces Q4 and Full-Year 2025 Financial Results Date
NASDAQ: $VKTX Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel therapeutics for metabolic and endocrine diseases, has officially announced the date for its upcoming financial report. Investors and interested parties can anticipate the company’s financial results for the fourth quarter and the full year ended December 31, 2025, which will be released…
-
Decoy Therapeutics Highlights Global Access Commitment Following Investor Presentation
NASDAQ: $DCOY Decoy Therapeutics Showcases Commitment to Global Accessibility During Recent Investor Event Decoy Therapeutics, Inc. recently participated in a dedicated segment during a virtual investor conference, focusing a significant portion of its presentation on the implications and execution strategy of its recently announced Global Access Commitment Agreement. The company utilized this platform to elaborate…
-
Pharos AI and 10x Genomics Join Forces to Advance Cancer Research Through Integrated Technology
NASDAQ: $TXG A significant collaboration has been established between Pharos AI, a leader in artificial intelligence solutions for the life sciences, and 10x Genomics, a pioneer in single cell and spatial biology technologies. This partnership is set to revolutionize how researchers approach complex challenges in oncology by integrating advanced computational power with cutting-edge molecular analysis.…